Sugi Predict

Sugi Predict / Compounds / SCHEMBL764029

SCHEMBL764029

SCHEMBL764029

CCOc1cccc(/C=C/C(=O)O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 1.00
▸ ALDH1A1 P00352 2/20 1.00
▸ SMN1; SMN2 Q16637 1/20 1.00
▸ PKM P14618 1/20 0.69
▸ POLB P06746 1/20 0.58
▸ HDAC4 P56524 1/20 0.56
▸ MEF2D Q14814 1/20 0.56
▸ MAOA P21397 1/20 0.55
▸ MAOB P27338 1/20 0.55
▸ LMNA P02545 1/20 0.54
▸ KMT2A Q03164 3/20 0.53
▸ GAA P10253 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ RHOA P61586 1/20 0.52
▸ FOS P01100 1/20 0.51
▸ JUN P05412 1/20 0.51
▸ BCHE P06276 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3079558 1.00 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL28397201 0.88 KDM4E (0.78) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL28397202 0.88 KDM4E (0.78) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL19036262 0.88 ALDH1A1 (0.78) KDM4EALDH1A1SMN1; SMN2PKMHDAC4
SCHEMBL8784209 0.87 KDM4E (0.76) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL8784206 0.87 KDM4E (0.76) KDM4EALDH1A1SMN1; SMN2PKMPOLB
SCHEMBL21457379 0.85 ALDH1A1 (0.74) KDM4EALDH1A1SMN1; SMN2MAOAMAOB
SCHEMBL21457374 0.85 ALDH1A1 (0.74) KDM4EALDH1A1SMN1; SMN2MAOAMAOB
SCHEMBL19244360 0.85 KDM4E (0.74) KDM4EALDH1A1SMN1; SMN2PKMHDAC4
SCHEMBL19244362 0.85 KDM4E (0.74) KDM4EALDH1A1SMN1; SMN2PKMHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615087-B1 TARGETING NANOPARTICLES Texas Childrens Hospital (US) 2023-09-06 — — EP disclosed
CN-111093717-B Targeted nanoparticles 德克萨斯州儿童医院 2023-01-31 — — CN disclosed
US-11312685-B2 Targeting nanoparticles TEXAS HEART INSTITUTE (US) 2022-04-26 — — US disclosed
US-11312685-B2 Targeting nanoparticles TEXAS HEART INSTITUTE (US) 2022-04-26 — — US disclosed
US-20210188774-A1 Targeting Nanoparticles TEXAS CHILDREN'S HOSPITAL 2021-06-24 — — US disclosed
US-20210188774-A1 Targeting Nanoparticles TEXAS CHILDREN'S HOSPITAL 2021-06-24 — — US disclosed
CN-110769864-B Gel deodorant 艾饰庭株式会社 2021-05-07 — — CN disclosed
CN-111093717-A Therapeutic nanoparticles 德克萨斯州儿童医院 2020-05-01 — — CN disclosed
EP-3615087-A1 TARGETING NANOPARTICLES Texas Children's Hospital (US) 2020-03-04 — — EP disclosed
CN-110769864-A Gel deodorant 艾饰庭株式会社 2020-02-07 — — CN disclosed
EP-1636212-A1 CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS Warner-Lambert Company LLC (US) 2006-03-22 — — EP disclosed
WO-2004108714-A1 CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 — — WO disclosed
WO-2004108716-A1 3-ARYLSULFANYL AND 3-HETEROARYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 — — WO disclosed
US-20040248954-A1 Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents GOGLIOTTI ROCCO DEAN (US) 2004-12-09 — — US disclosed
US-20040248953-A1 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents GOGLIOTTI ROCCO DEAN (US) 2004-12-09 — — US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
EP-0855387-A1 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS KISSEI PHARMACEUTICAL CO., LTD. (JP) 1998-07-29 — — EP disclosed
CN-85109752-A Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds — 1986-12-17 — — CN disclosed
US-3962282-A JUVENILE HORMONE MIMICS ELI LILLY AND COMPANY (US) 1976-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248954-A1 Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents MALT1, BPNT1, CYP1B1 KDM4E 3607/4885ALDH1A1 265/4885SMN1; SMN2 3825/4885
US-20210188774-A1 Targeting Nanoparticles PHOSPHO1, CD47, ITGB3 KDM4E 1682/4885ALDH1A1 2701/4885SMN1; SMN2 1093/4885
US-20040248953-A1 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents SULT2A1, SULT1A1, SULT1E1 KDM4E 3209/4885ALDH1A1 157/4885SMN1; SMN2 3612/4885
US-11312685-B2 Targeting nanoparticles PHOSPHO1, CD47, ITGB3 KDM4E 1682/4885ALDH1A1 2701/4885SMN1; SMN2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.